智通财经APP获悉，和黄医药(00013)涨超5%，截至发稿，涨5.39%，报25.4港元，成交额2.04亿港元。
里昂发布研报指出，近日，和黄医药在美国临床肿瘤学会(ASCO)年会上，公布赛沃替尼(savolitinib)和奥希替尼(osimertinib)联合疗法用于治疗非小细胞肺癌中国三期临床试验的最新研究结果。该行指出，中期分析结果显示，与对照组相比，赛沃替尼联合奥希替尼的治疗显示出不俗疗效及良好安全性，管理层提到总生存期趋势向好但尚未成熟。该行预期新研究数据应有利于赛沃替尼在中国的适应症扩展。
据悉，赛沃替尼是中国首个获批的高选择性MET抑制剂，为MET外显子14跳跃突变的NSCLC患者提供了新的治疗选择，填补了国内该领域的空白。其疗效明确，安全性可控，但需在医生指导下合理用药，并密切监测不良反应。随着研究的深入，赛沃替尼在其他MET异常肿瘤(如肾癌、胃癌等)中的应用也在探索中。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.